Solution

We are developing next-generation oral obesity therapies—rooted in validated biology and powered by AI.

Pharma Consult v. Niels Porksen brings together Big Pharma expertise with agility and innovation. Our model is targeted, efficient, and far more cost-effective than traditional approaches. While conventional drug development often exceeds 10 years and $2 billion in costs, we aim to bring new drug candidates to clinical readiness in under four years and for less than €10 million.

We focus exclusively on clinically validated targets—such as Amylin and GIP—and leverage advanced AI technology from partners like Kvantify to enhance compound design. This approach minimizes risk at each stage and accelerates progress from hit to lead to preclinical candidate.

Our modular development model is designed to attract strategic investors early in the process. Each drug asset is structured as an independent entity with clear exit opportunities—either upon candidate nomination or at Proof of Concept stage. This enables flexibility, scalability, and a clear path to value creation.

Our goal is simple but ambitious: to deliver best-in-class oral therapeutics that can replace injectables and transform how obesity is treated around the world. Backed by a global network of experts, proven technology, and a lean innovation model, we are ready to lead the next chapter in obesity care.

Do you have any questions or would you like a non-binding offer?

Contact LeanBio today for competent sparring and advice

are you interested?

You want to hear more?

Let’s connect. Whether you’re looking to collaborate, invest, or explore how our approach to small molecule obesity treatment can create real-world impact, we’re ready to share our vision and progress with you.